These findings further support that the inhibition of hepatic PTP1B and LMPTP contributes to the improvement of liver metabolism and may provide new insights into the development of valuable therapeutic strategies to prevent the lipotoxic states that occur in NAFLD. Here, PTPN1 is linked to metabolic dysfunction-associated steatotic liver disease.